Correlation between prostate specific antigen and prostate volume with disease symptom severity assessed by international prostate symptom score

Nikhar Salvi; Sunil Vyas; Ravi Bhatt; Priyesh Patel; Sujan Patel; Chetan Agarwal

doi:10.18203/2320-6012.ijrms20230866

Authors

Nikhar Salvi Department of Surgery, Pramukhswami Medical College, Karamsad, Anand, Gujarat, India
Sunil Vyas Department of Surgery, Pramukhswami Medical College, Karamsad, Anand, Gujarat, India
Ravi Bhatt Department of Surgery, Pramukhswami Medical College, Karamsad, Anand, Gujarat, India
Priyesh Patel Department of Surgery, Pramukhswami Medical College, Karamsad, Anand, Gujarat, India
Sujan Patel Department of Surgery, Pramukhswami Medical College, Karamsad, Anand, Gujarat, India
Chetan Agarwal Department of Surgery, Pramukhswami Medical College, Karamsad, Anand, Gujarat, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20230866

Keywords:

BPH, IPSS, Prostate, Prostate volume, PSA

Abstract

Background: Benign prostatic hyperplasia (BPH) is clinically defined as prostate adenoma, resulting in bladder outlet obstruction (BOO), which may eventually harm the bladder and even kidneys. For differential diagnosis of male LUTS, uroflowmetry can be used together with non-invasive ultrasound to ascertain the flow rate and IPP. PSA is also an important indicator for differential diagnosis. International prostate symptoms score (IPSS) is used to assess the severity of the symptoms for clinical BPH. There is also a recommendation to consider the quality of life (QoL) index, where a QoL score of ≥3 is considered as worrisome.

Methods: This was a retro-prospective study based on secondary and primary data collection and analysis, pertaining to BPH patients who visited the study site previously as well as those who are coming for regular follow-up since 2019. Patient enrolment was done at a teaching hospital Shree Krishna Hospital affiliated to the Pramukh Swami Medical College, Bhaikaka University, Karamsad. About 100 patients presenting with lower urinary tract symptoms (LUTS) and histo-pathologically proven cases of BPH were enrolled to pursue research objectives. All patients were followed up to a period of 3-months after initiating the treatment and disease severity through IPSS and quality of life upon completion of treatment were also assessed.

Results: PSA is also an important indicator for differential diagnosis, which is generally less than 1 μg/l in patients in absence of clinically confirmed BPH. In our study, mean prostate volume was reported to be 43.46±19.35 cc. A positive correlation was observed between prostate volume and serum PSA with disease severity.

Conclusions: Our study evaluated the IPSS to predict the disease severity and correlated it with quality of life, prostate volume and serum PSA. Our findings were in line with currently available evidences, and suggested that QoL, prostate volume and serum PSA are better predictors of disease severity, IPSS.

Metrics

Metrics Loading ...

References

Luo GC, Foo KT, Kuo T, Tan G. Diagnosis of prostate adenoma and the relationship between the site of prostate adenoma and bladder outlet obstruction. Singapore Med J. 2013;54(9):482-6.

Foo KT. Pathophysiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):152-7.

Tan YH, Foo KT. Predicting the outcome of trial voiding following acute urinary retention using transabdominal ultrasound. J Urol. 2001;165(6):269.

Foo KT, Lee LS. Re: intravesical prostatic protrusion (IPP) and uroflowmetry in the management of benign prostatic enlargement (BPE). Int J Urol. 2010;17(6):589

Foo KT. Current assessment and proposed staging of patients with benign prostatic hyperplasia. Ann Acad Med Singapore. 1995;24(4):648-51

Ganpule AP, Desai MR, Desai MM, Wani KD, Bapat SD. Natural history of lower urinary tract symptoms: preliminary report from a community-based Indian study. BJU Int. 2004;94:332-4.

Choo MS, Yoo C, Cho SY, Jeong SJ, Jeong CW, Ku JH, et al. Development of decision support formulas for the prediction of bladder outlet obstruction and prostatic surgery in patients with lower urinary tract symptom/benign prostatic hyperplasia: part i, development of the formula and its internal validation. Int Neurourol J. 2017;21(1):S55-65.

Thorlund K, Cartwright R, Tammela TLJ, Guyatt GH, Auvinen A, Tikkinen KAO. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol. 2014;65:1211-7.

Mirone V, La Rocca R, Franco M, Venturino L. Pathologic triggers related to LUTS and BPHt. In: Lower urinary tract symptoms and benign prostatic hyperplasia. London Wall, London: Elsevier; 2018:15-29.

Naber KG. Chronic prostatitis- an infectious disease? J Antimicrob Chemother. 2000;46:157-61.

Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol. 1997;31:272-80.

Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol. 2004;172(4 pt 1):1390-3.

McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12(5):S122-8.

Jin B, Turner L, Zhou Z, Zhou EL, Handelsman DJ. Ethnicity and migration as determinants of human prostate size. J Clin Endocrinol Metab. 1999;84:3613-9.

Masumori N, Tsukamoto T, Kumamoto Y, Miyake H, Rhodes T, Girman CJ, et al. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community-based studies in 2 countries. J Urol. 1996;155(4):1324-7.